PriceTargets.com logo

Fulcrum Therapeutics - FULC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.71
  • Forecasted Upside: 238.51 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$6.71 As of 11/28/2022 01:00 AM ET
▼ -0.14 (-2.04%)

This chart shows the closing price for FULC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fulcrum Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FULC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FULC

Analyst Price Target is $22.71
▲ +238.51% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Fulcrum Therapeutics in the last 3 months. The average price target is $22.71, with a high forecast of $35.00 and a low forecast of $11.00. The average price target represents a 238.51% upside from the last price of $6.71.

This chart shows the closing price for FULC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Fulcrum Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/3/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/1/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/30/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2022OppenheimerLower Target$30.00Low
11/15/2022The Goldman Sachs GroupInitiated CoverageBuy$11.00Low
11/14/2022Morgan StanleyBoost TargetOverweight$25.00 ➝ $26.00Low
11/9/2022Credit Suisse GroupLower TargetOutperform$22.00 ➝ $19.00Low
11/8/2022Piper SandlerLower Target$42.00 ➝ $18.00Low
10/20/2022Stifel NicolausLower Target$43.00 ➝ $35.00Low
8/15/2022Credit Suisse GroupLower Target$22.00N/A
8/12/2022HC WainwrightReiterated RatingBuy$20.00Low
6/10/2022HC WainwrightReiterated RatingBuy$20.00High
5/27/2022Stifel NicolausReiterated RatingBuy$43.00High
5/17/2022Morgan StanleyLower TargetOverweight$25.00Low
4/12/2022Morgan StanleyBoost TargetOverweight$25.00 ➝ $26.00High
3/25/2022Credit Suisse GroupBoost TargetOutperform$30.00 ➝ $35.00High
3/7/2022OppenheimerInitiated CoverageOutperform$33.00Medium
3/4/2022HC WainwrightInitiated CoverageBuy$40.00High
3/3/2022Piper SandlerLower Target$46.00 ➝ $42.00High
3/3/2022Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
8/17/2021Piper SandlerBoost TargetHold ➝ Overweight$20.00 ➝ $46.00Low
8/17/2021HC WainwrightBoost TargetPositive ➝ Buy$20.00 ➝ $40.00Low
8/15/2021SVB LeerinkReiterated RatingBuy$23.00Low
8/13/2021SVB LeerinkBoost TargetOutperform$23.00 ➝ $37.00Low
8/11/2021Credit Suisse GroupBoost TargetPositive ➝ Outperform$20.00 ➝ $30.00Low
8/11/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$12.00 ➝ $34.00High
8/10/2021Stifel NicolausBoost TargetBuy$39.00 ➝ $45.00High
6/24/2021Stifel NicolausBoost TargetBuy$20.00 ➝ $39.00High
4/12/2021HC WainwrightReiterated RatingBuy$20.00Medium
3/22/2021Credit Suisse GroupInitiated CoverageOutperform$26.00High
3/8/2021Morgan StanleyBoost TargetEqual Weight$11.00 ➝ $12.00High
3/4/2021Piper SandlerLower TargetOverweight$22.00 ➝ $20.00High
3/1/2021Stifel NicolausInitiated CoverageBuy$18.00High
11/10/2020SVB LeerinkLower TargetOutperform$25.00 ➝ $23.00High
10/15/2020Piper SandlerInitiated CoverageOverweight$22.00Medium
8/12/2020BTIG ResearchLower Target$27.00 ➝ $22.00High
8/12/2020Bank of AmericaDowngradeNeutral ➝ Underperform$11.00High
8/12/2020HC WainwrightLower TargetBuy$28.00 ➝ $20.00High
8/12/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$29.00 ➝ $11.00High
6/19/2020Bank of AmericaDowngradeBuy ➝ Neutral$19.00 ➝ $23.00High
6/17/2020Raymond JamesUpgradeMarket Perform ➝ OutperformHigh
6/16/2020BTIG ResearchInitiated CoverageBuy$27.00High
3/6/2020HC WainwrightReiterated RatingBuy$21.00 ➝ $28.00High
12/24/2019HC WainwrightReiterated RatingBuy$21.00Medium
10/3/2019HC WainwrightInitiated CoverageBuy$21.00High
8/12/2019SVB LeerinkReiterated RatingOutperformHigh
8/12/2019Morgan StanleyInitiated CoverageOverweight$29.00High
8/12/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$19.00High
(Data available from 11/28/2017 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2022
  • 6 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
6/1/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/31/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/30/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2022
  • 4 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/28/2022

Current Sentiment

  • 4 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Fulcrum Therapeutics logo
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $6.71
Low: $6.63
High: $7.05

50 Day Range

MA: $6.94
Low: $5.01
High: $8.79

52 Week Range

Now: $6.71
Low: $3.21
High: $24.79

Volume

227,275 shs

Average Volume

567,403 shs

Market Capitalization

$349.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Fulcrum Therapeutics?

The following Wall Street analysts have issued reports on Fulcrum Therapeutics in the last year: Bank of America Co., Credit Suisse Group AG, HC Wainwright, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Stifel Nicolaus, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for FULC.

What is the current price target for Fulcrum Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Fulcrum Therapeutics in the last year. Their average twelve-month price target is $22.71, suggesting a possible upside of 238.5%. Stifel Nicolaus has the highest price target set, predicting FULC will reach $35.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $11.00 for Fulcrum Therapeutics in the next year.
View the latest price targets for FULC.

What is the current consensus analyst rating for Fulcrum Therapeutics?

Fulcrum Therapeutics currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FULC will outperform the market and that investors should add to their positions of Fulcrum Therapeutics.
View the latest ratings for FULC.

What other companies compete with Fulcrum Therapeutics?

Other companies that are similar to Fulcrum Therapeutics include Kinnate Biopharma, Khosla Ventures Acquisition, Wave Life Sciences, Heron Therapeutics and Organogenesis. Learn More about companies similar to Fulcrum Therapeutics.

How do I contact Fulcrum Therapeutics' investor relations team?

Fulcrum Therapeutics' physical mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 651-8851 and its investor relations email address is [email protected] The official website for Fulcrum Therapeutics is www.fulcrumtx.com. Learn More about contacing Fulcrum Therapeutics investor relations.